8-K: Butterfly Network Achieves Record Q4 Revenue, Positive Cash Flow

Butterfly Network reported record quarterly revenue of $31.5 million in Q4 2025, marking 41% year-over-year growth and achieving its first quarter of positive operating cash flow.

Summary

• Achieved record quarterly revenue of $31.5 million in Q4 2025, representing 41% year-over-year growth.
• Generated positive net cash flow of $6.3 million in Q4 2025, marking the first quarter of positive operating cash flow in company history.
• Reported the lowest annual cash usage in company history for the year ended December 31, 2025.
• The Midjourney partnership contributed $6.8 million of revenue in Q4 2025, advancing the Butterfly Embedded platform strategy.
• Total revenue for the full year 2025 was $97.6 million, an increase from $82.0 million in 2024.
• Net loss for Q4 2025 improved to $15.3 million, compared to $18.1 million in Q4 2024.
• Adjusted EBITDA loss for Q4 2025 was $3.2 million, a significant improvement from $9.1 million in Q4 2024.
• Cash and cash equivalents stood at $150.5 million as of December 31, 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, demonstrating significant progress in revenue growth, cash flow management, and strategic execution, particularly with the Midjourney partnership and the shift towards a semiconductor-based platform.

Positives

• Record quarterly revenue of $31.5 million in Q4 2025, a 41% year-over-year increase.
• Achieved the first quarter of positive operating cash flow in company history, generating $6.3 million in Q4 2025.
• Realized the lowest annual cash usage in company history.
• U.S. revenue increased by 55% year-over-year to $26.8 million in Q4 2025, driven by the Midjourney partnership and increased probe sales.
• GAAP gross margin increased to 67.3% and adjusted gross margin to 67.5% in Q4 2025, up from 61.4% in Q4 2024, primarily due to higher margin licensing revenue.
• Net loss improved to $15.3 million in Q4 2025 from $18.1 million in Q4 2024.
• Adjusted EBITDA loss significantly reduced to $3.2 million in Q4 2025 from $9.1 million in Q4 2024.
• Adjusted EPS improved to $(0.02) in Q4 2025 from $(0.05) in Q4 2024.
• The Midjourney partnership contributed $6.8 million in Q4 revenue, validating the Butterfly Embedded platform strategy.
• Successfully launched Compass AI, a next-generation enterprise software, supporting existing accounts and enterprise pipeline growth.
• Achieved GovRAMP and TX-RAMP authorizations in the U.S., strengthening the ability to serve federal and Department of Defense markets.
• Advanced R&D roadmap by moving the fifth-generation P5.1 chip into production and progressing Apollo development for next-generation AI-enabled imaging.
• Cash and cash equivalents increased to $150.5 million as of December 31, 2025, from $88.7 million at December 31, 2024.

Negatives

• International revenue decreased 6% year-over-year to $4.7 million in Q4 2025, largely due to increased sales to new distribution partners in the prior year.
• Operating expenses increased 22% to $37.9 million in Q4 2025 from $31.0 million in Q4 2024.
• The company still reported a net loss of $15.3 million in Q4 2025 and an Adjusted EBITDA loss of $3.2 million.
• Full year 2025 net loss was $77.1 million, an increase from $72.5 million in 2024.

Risks

• Ability to grow and manage growth effectively.
• Success, cost, and timing of product and service development activities.
• The potential attributes and benefits of products and services, and the degree to which they are accepted by healthcare practitioners and patients.
• Ability to obtain and maintain regulatory approval for products, and any related restrictions and limitations on use.
• Ability to identify, in-license, or acquire additional technology.
• Ability to maintain existing license, manufacturing, supply, and distribution agreements.
• Success, cost, and timing of efforts to out-license intellectual property to third parties.
• Ability to compete with other companies currently marketing or developing ultrasound imaging devices, many of which have greater financial and marketing resources.
• Changes in applicable laws or regulations.
• The size and growth potential of the markets for products and services, and the ability to serve those markets.
• The pricing of products and services, and reimbursement for medical procedures conducted using them.
• Estimates regarding expenses, revenue, capital requirements, and needs for additional financing.
• Ability to attract and retain customers.
• Ability to protect or enforce intellectual property rights.
• Ability to maintain the listing of Class A common stock on the New York Stock Exchange.

Future Outlook

For Fiscal Year 2026, Butterfly Network projects total revenue between $117 million and $121 million, representing approximately 20% to 24% growth. The company also anticipates an Adjusted EBITDA loss ranging from $21 million to $25 million.

Management Comments

• "Our fourth quarter 2025 performance shows that our strategy is taking hold and our vision is becoming tangible."
• "We delivered record quarterly revenue of $31.5 million, growing 41% year over year, and achieved the first quarter of positive operating cash flow in our company's history."
• "Nearly two years into our strategic plan, we are executing with financial discipline, strengthening our core point-of-care business, and now realizing material organic revenue from new initiatives."
• "Butterfly is transitioning from a medical device company into a transformative semiconductor-based company building the foundation for programmable, AI-native imaging and sensing."
• "From expanding enterprise adoption in point-of-care, to building HomeCare into a commercial business, to enabling entirely new applications through Butterfly Embedded, it's all powered by the same proprietary Ultrasound-on-Chip technology. One platform and one diversified strategy that puts us in a strong position to execute and win."

Industry Context

StockSavvy.ai notes that Butterfly Network's shift from a pure medical device company to a semiconductor-based, AI-native imaging and sensing platform aligns with broader trends in MedTech, where miniaturization, AI integration, and data-driven insights are becoming paramount. The strategic partnerships, like with Midjourney, demonstrate a move towards diversified revenue streams beyond traditional hardware sales, a common strategy for companies seeking to expand market reach and leverage core technological assets in new verticals.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Positive impact due to record revenue, improved profitability metrics (reduced losses), positive operating cash flow, and strategic advancements that could drive future growth. The share offering in 2025 indicates capital infusion.
• Employees: Continued investment in sales force and client experience function suggests stability and potential growth opportunities.
• Customers: Benefits from new product launches (Compass AI, iQ3), improved performance (P5.1 chip, Apollo development), and expanded market access (GovRAMP, TX-RAMP).
• Partners (e.g., Midjourney): Strong validation of the co-development model and Butterfly Embedded platform, indicating successful collaboration and potential for further partnerships.

Next Steps

• Finalizing the first commercial HomeCare agreement by mid-2026.
• Anticipated revenue contributions from HomeCare commercialization as early as late 2026 and into 2027.
• Continued advancement of Apollo development for next-generation AI-enabled imaging and partner applications.
• Plan to release Butterfly's proprietary digital 3D beam steering API to third parties via the Butterfly Garden Program.

Key Dates

Recommendation

The filing indicates a significant positive inflection point for Butterfly Network, with record revenue growth, the achievement of positive operating cash flow for the first time, and substantial improvements in key profitability metrics. The strategic shift towards a semiconductor-based, AI-native platform, validated by the Midjourney partnership, positions the company for long-term growth in new markets. While still operating at a net loss, the trajectory of financial improvement and strategic execution suggests strong future potential, making it an attractive investment for growth-oriented portfolios.

Keywords

Ultrasound-on-Chip, digital health, medical imaging, AI, semiconductor, point-of-care, HomeCare, Butterfly Embedded, Q4 2025 earnings, financial results, BFLY, MedTech, diagnostic imaging